JOHNSON & JOHNSON
NEW BRUNSWICK, NJ · Quarter end: Sep 30, 2026 · Filed with SEC: Oct 26, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$761.7M2026 Q3
Positions15
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.98.8%
Top Holdings
PTGX
Protagonist Therapeutics
45.3%
NBTX
Nanobiotix S.A.
23.0%
MGTX
MeiraGTx
9.6%
RAPP
Rapport Therapeutics
7.9%
CTNM
Contineum Therapeutics
3.5%
CBRS
Cerebras Systems
3.0%
XNCR
Xencor
2.5%
LEGN
Legend Biotech
2.1%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.